Role of mitochondrial ribosomal protein S18-2 in cancerogenesis and in regulation of stemness and differentiation by Mushtaq, Muhammad
From THE DEPARTMENT OF MICROBIOLOGY TUMOR AND 
CELL BIOLOGY (MTC) 
Karolinska Institutet, Stockholm, Sweden 
ROLE OF MITOCHONDRIAL RIBOSOMAL 
PROTEIN S18-2 IN CANCEROGENESIS 
AND IN REGULATION OF STEMNESS AND 
DIFFERENTIATION 
Muhammad Mushtaq 
 
Stockholm 2017 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2017 
© Muhammad Mushtaq, 2017 
ISBN 978-91-7676-697-2 
Role of Mitochondrial Ribosomal Protein S18-2 in 
Cancerogenesis and in Regulation of Stemness and 
Differentiation 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Muhammad Mushtaq 
Principal Supervisor: 
Associate Professor Elena Kashuba 
Karolinska Institutet 
Department of Microbiology Tumor and Cell 
Biology (MTC) 
 
Co-supervisor(s): 
Professor Sonia Lain 
Karolinska Institutet 
Department of Microbiology Tumor and Cell 
Biology (MTC) 
 
Professor George Klein 
Karolinska Institutet 
Department of Microbiology Tumor and Cell 
Biology (MTC) 
Faculty Opponent: 
Professor Pramod Kumar Srivastava 
University of Connecticut 
Center for Immunotherapy of Cancer and 
Infectious Diseases 
 
Examination Board: 
Professor Ola Söderberg 
Uppsala University 
Department of Immunology, Genetics and 
Pathology (IGP) 
 
Professor Boris Zhivotovsky 
Karolinska Institutet 
Institute of Environmental Medicine (IMM) 
 
Professor Lars-Gunnar Larsson 
Karolinska Institutet 
Department of Microbiology Tumor and Cell 
Biology (MTC) 
  
 
 
 
 
 
 
 
 
 
 
Dedicated to my parents 
  
ABSTRACT 
Mitochondria carry their own ribosomes (mitoribosomes) for the translation of mRNA 
encoded by mitochondrial DNA. The architecture of mitoribosomes is mainly composed of 
mitochondrial ribosomal proteins (MRPs), which are encoded by nuclear genomic DNA. 
Emerging experimental evidences reveal that several MRPs are multifunctional and they 
exhibit important extra-mitochondrial functions, such as involvement in apoptosis, protein 
biosynthesis and signal transduction. Dysregulations of the MRPs are associated with severe 
pathological conditions, including cancer. Cancer cells are immortal, i.e. they proliferate in 
limitless mode, avoiding cell cycle control which is a characteristic of normal cells. 
Retinoblastoma susceptibility (RB) protein is the major regulator of cell cycle and it operates 
by inhibiting the activity of E2F1 transcription factor through direct binding. 
This doctoral thesis is devoted to the extra-mitochondrial role of a RB interacting MRP, the 
MRP-S18-2 (or S18-2), in different aspects of cancer. S18-2 is localized to the small subunit 
of mitoribosome and it belongs to S18 family of MRPs, a family consisting of three proteins. 
Previously, it was shown that S18-2 binds to RB, inhibiting the association of the latter with a 
transcription factor E2F1 that regulates G1/S transition of cell cycle. Overexpression of S18-2 
in rat embryonic fibroblasts led to their immortalization with induction of stem cells markers. 
In this thesis, I describe that overexpression of S18-2 can also immortalize terminally 
differentiated rat skin fibroblasts. The immortalized cells displayed characteristics of 
transformed cells with severe chromosomal instability, disrupted cell cycle, enhanced 
telomerase activity and the ability to produce tumors in experimental animals. We also 
showed that rodent cells immortalized by S18-2 overexpression were targeted by NK cells 
mediated cytotoxicity.  
Phylogenetic analysis of S18 proteins revealed specific gene duplication events that resulted 
in three S18 homologs in metazoan. In addition, a Gly132 polymorphism in S18-2 was 
observed in colon adenocarcinoma that was confirmed by PCR analysis and direct DNA 
sequencing.  
The S18-2 protein level was increased, along with free E2F1, in endometrial cancer (EC). 
Moreover, high S18-2 levels may be associated with epithelial to mesenchymal transition in 
EC cells. Elevated levels of S18-2 were also found in prostate cancer (PCa). S18-2 could 
induce the CXCR4 mediated migration of PCa cells in vitro and in a zebrafish model. We 
also demonstrated new functional consequence of RB and S18-2 interaction in maintenance 
of a stem cell phenotype, using RB1 knockout mouse embryonic fibroblasts. A cytoplasmic 
protein complex between S18-2, RB and the Ring finger protein 2 (RNF2) was detected. This 
enhanced the E3 ligase activity of RNF2, thus, maintaining cell stemness.  
Our data supports and provide evidence to suggest that S18-2, a RB interacting protein, plays 
important roles in the development of cancer as a potent oncoprotein.  
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1 INTRODUCTION  
1.1 MITOCHONDRIA 
Mitochondria are present in all living organism from bacteria to plants and in humans. The 
origin of mitochondria is believed as a result of symbiosis more than 1.45 billion years ago. 
The earliest observations of mitochondria can be traced to 1840s [1]. However, in 1890 
Richard Altmann realized the appearance of such cellular organelles [2]. He named them 
"bioblasts" and suggested that they were "elementary organisms" residing and performing 
pivotal roles in the cells. The name mitochondrion was introduced by Carl Benda in 1898 [3]. 
This name originates from the Greek words "mitos" (thread) and "chondros" (granule), due to 
their appearance during spermatogenesis. 
Currently, two main theories explain the symbiotic derivation of mitochondria. They differ 
with regards to their speculation about the nature of host, the physiological capabilities of 
mitochondria and the type of ecological factors that were involved in successful symbiosis 
[4]. The traditional view postulates that mitochondrion was engulfed by an anaerobic 
nucleus-bearing eukaryotic host cell via phagocytosis. The competing theory posits that a 
prokaryote which was most probably an archaebacterium acquired the mitochondrion.  
Mitochondria are diverse among species. In contrast to mammalian mitochondria, the 
mitochondria of certain invertebrates do not utilize oxygen. Such anaerobic mitochondria 
generate about 5 moles of adenosine triphosphate (ATP) per mole of glucose, contrary to 36 
moles generated during aerobic respiration. Yet another type of mitochondria is found in 
protists eukaryotes, called hydrogenosomes which produce hydrogen as a major metabolic 
end product. Hydrogenosomes produce only 4 moles of ATP per glucose molecule [5]. The 
mitochondria of eukaryotic parasites like Entamoeba histolytica are called mitosomes, which 
do not produce any ATP molecules [4]. 
1.1.1 Mitochondrial structure and function 
Mitochondria are diverse in structure and size, ranging between 0.75 to 3μm2 across different 
species [6]. They are considered as autonomous cell organelles due to the following reasons: 
1) they carry their own DNA which can replicate independently; 2) they possess their own 
ribosomes, namely, mitoribosomes; 3) mitochondria can synthesize some of their own 
structural proteins. The typical mammalian mitochondria have a double membrane structure 
whose lumen is filled with mitochondrial matrix [7]. The outer membrane of mitochondria is 
permeable to pyruvate [8], oxygen [9], ATP [10] and certain other molecules. The inner 
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membrane is intricated into many invaginated structures known as ‘‘cristae’’. The shape of 
the cristae is often flat or tubular but in some cases the number and shape of the cristae may 
vary. For example, in certain nerve cells, the cristae take the form of prisms [11] while in 
some photoreceptor cone cells they have a spiral shape [12]. The shape of the cristae is 
associated with the regulation of ATP synthesis in mitochondria [13]. The cristae are covered 
with many small stalked particles named inner membrane spheres. Each sphere is composed 
of a stalk and a sphere (head) [14]. The sphere is on the matrix side and it contains an enzyme 
called F1. This enzyme is involved in the production of ATP [15]. 
 
Figure 1: Mitoribosome. Each mitoribosome is comprised of SSU (red) and LSU (blue). The 
MRPs are encoded by genomic DNA in the nucleus, the product is processed in cytoplasm 
and then transported to mitochondria. Figure was drawn using Chem Biodraw software. 
Mitochondria are also called power house of the cell because they fuel cells with energy in 
the form of ATP through the process of oxidative phosphorylation (OXPHOS). In the 
cytosol, glucose is catabolized to pyruvate in the process of glycolysis [16, 17]. Pyruvate 
transverses the outer membrane of mitochondria through porin (voltage dependent anion 
channel) [18]. In mitochondria, the pyruvate dehydrogenase complex system converts 
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pyruvate to acetyl-CoA [19] that take part in the tri-carboxylic acid (TCA) cycle (also termed 
as Kreb’s cycle). 
The TCA cycle is comprised of 10 biochemical reactions oxidizing two carbon atoms acetyl-
CoA to carbon dioxide. The end product of the TCA cycle is the reduced form of 
Nicotinamide adenine dinucleotide (NADH) [20]. The products of TCA; NADH and FADH2 
enter the electron transport chain (ETC), a sequential process of electron transfer between 
electron accepting and donating molecules that ends with ATP at the expense of oxygen. The 
ETC, which combines phosphorylation and oxidation, is composed of four multi-subunit 
complexes (Complex I-IV) along with ATP synthase (Complex V). The protein complexes 
involved in the ETC are encoded by both the mitochondrial and nuclear genome [21].  
The five multimeric protein complexes of ETC are: NADH dehydrogenase, an ubiquinone 
oxidoreductase (complex I composed of about 46 subunits), succinate dehydrogenase another 
ubiquinone oxidoreductase (complex II containing four subunits), an ubiquinone 
cytochrome c oxidoreductase (complex III of 11 subunits), cytochrome c oxidase (complex 
IV comprised of 13 subunits), and ATP synthase (complex V, consist of 16 subunits). ATP 
synthesis is a two-step process; firstly, electrons derived from NADH and FADH2 are 
delivered to molecular oxygen through different mitochondrial complexes, producing water. 
In the next step protons are pumped through the inner membrane by complexes I, III, and IV, 
generating an electrochemical gradient [22]. 
1.1.2 Mitochondrial ribosome  
In 1963, mitochondrial DNA (mtDNA) was discovered in the embryos of chicken, as fibers 
exhibiting the DNA like characteristics [23]. The DNA of mammalian mitochondria is 
circular [24] and is acquired by offspring solely from the mother [25, 26]. It was shown that 
after fertilization the paternal mtDNA of the sperm is tagged by ubiquitin and degraded in the 
embryo [27]. The mtDNA encodes 37 genes, including the 12S and 16S rRNAs, the 22 
mitochondrial tRNAs and 13 essential peptides of OXPHOS system [28]. In human, a 14th 
biologically active protein was discovered, named humanin [29]. It is encoded by mtDNA; 
however, unlike other mitochondrial proteins, humanin does not localize in mitochondria. 
The 13 mRNA related to OXPHOS are translated to protein by mitoribosomes (Figure 1). In 
1967 Thomas O’Brien and co-workers isolated the mitoribosomes from rat liver 
mitochondria [30]. 
During the evolution of mammalian mitoribosome (55S), the ancestral mitoribosome (70S) 
underwent key structural alterations. The 55S mitoribosome contains more proteins than the 
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bacterial ribosome; therefore, mammalian mitorobosomes are larger than bacterial ribosomes 
despite the loss of approximately half of their RNA [31]. 
Mammalian 55S mitoribosome is composed of two subunits: the 28S small subunit (SSU) 
and the 39S large subunit (LSU) [32-34]. The SSU is involved in mRNA binding [32] and 
decoding, whereas the LSU assists the mitoribosome in catalysis of peptidyl transferase 
reactions [35].  
The mitochondrial ribosomal proteins (MRPs) are encoded by nuclear genomic DNA. Their 
mRNAs are transcribed in the nucleus, then MRPs are synthesized in cytoplasm before they 
are transported to the mitochondria (see Figure 1). Generally, the N terminus of MRPs is 
responsible for the translocation of these proteins to mitochondria [36-40]. Recently, the 
crystallographic structure of mammalian 55S mitoribosome was resolved at a resolution of 
3.8Å, using cryo-electron microscopy [41].  
1.1.3 Mitochondrial ribosomal proteins of small and large subunits 
The LSU of mammalian mitoribosome carries 52 MRPs. It carries 11 extra proteins 
compared to the 54S LSU of yeast mitoribosome [35]. Some of the featured parts of LSU are 
peptidyl transferase center (PTC), the polypeptide exit site (PES), central protuberance (CP) 
and exit site (TE). The PTC is formed exclusively of rRNA and it catalyses peptide bond 
formation; MRPL59 may be involved in protein–RNA interactions in this region. At the CP, 
MRPL48 and MRPL40 may form a portion of the P-site finger. Other important MRPLs in 
CP region are MRPL38, MRPL18, MRPL40, MRPL46, MRPL48 and MRPL55. The nascent 
protein leaves the ribosome at PEC. In LSU, PES starts at the end of PTC and leads through 
the LSU to the polypeptide exit site. The PES region plays an important role in processing, 
folding and targeting of nascent polypeptides. In bacteria, this sequence is targeted by 
antibiotics [35]. 
The SSU of mitoribosomes contains 12S rRNA and 30 MRPs, 15 of which are specific to 
mammalian mitoribosomes. Fourteen have homologues in 30S ribosomal proteins of E. coli 
and more in D. melanogaster, C. elegans, and S. cerevisiae [32, 39]. The overall structure of 
SSU is elongated and is divided in three distinct regions; head, platform and foot [42] as 
shown in Figure 3. The head portion is recognized by presence of MRPS29 which is GTP 
binding protein, it was shown to be phosphorylated in vivo and is involved in inter sub unit 
bridge formation [43]. The foot carry MRPS27 which is penta-tricopeptide repeat (PPR) 
domain protein [44]. MRPS27 binds with tRNA (Glu) and 12S rRNA and these bindings are 
essential for translation, because MRPS27 knockdown causes deficiency in cytochrome c 
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oxidase activity and decreased abundance in respiratory complexes [45]. The mRNA entrance 
site in SSU is composed of MRPS5, MRPS24, and MRPS39. The diameter of the entrance 
site is constrained, shorter than the two strands of RNA therefore only single stranded mRNA 
(ssRNA) can pass. At the entry region, another PPR repeat protein (MRPS39) is located 
which binds mRNA molecules and direct them through the ribosomal channel. The exit site is 
mainly composed of MRPS28 and MRPS37. Unlike the bacterial homolog, mammalian 
MRPS28 strongly binds with ribosome through interactions with MRPS2 and MRPS21 [2, 
44]. The SSU also display intrinsic GTPase activity [46] due to the presence of MRPS29 in 
the head, it binds with the 12S rRNA as well as MRPS7, MRPS9, and MRPS35. Such 
bindings result in inter-sub unit bridging between SSU and LSU [41].  
1.1.4 S18 family of mitochondrial ribosomal proteins. 
The MRPS18 (termed S18 here) proteins are grouped in a family, consisting of three 
homologs in metazoa (S18-1–3) and one homolog in other cellular organisms. S18-1 and 
S18-2 are localized on the SSU while S18-3 is present on LSU. Three S18 proteins 
remarkably differ in structure (Figure 2) and size, ranging from 11.7 to 27 kDa [28]. The gene 
sequences of S18 are remarkably different among each other suggesting that they might 
perform different functions [47]. The sequence of S18 homologs are found to be more closely 
related to chloroplast S18 than to prokaryotic S18 [47]. The S18-1 gene lies on chromosome 
4q21.23 [48], whereas S18-2 is located on chromosome 6p21.3.1 [48] (adjacent to the genes 
encoding the MHC class II proteins) and S18-3 was mapped to chromosome 6p21.3 [49]. 
Figure 2: The crystal structure of S18 family of MRPs. Figure depicts that S18 proteins are 
structurally very distinct from each other. The structures were isolated using Pymol software 
from the entire 55S mitoribosome structure reported in [41].  
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Previously it was assumed that mitoribosomes are highly heterogeneous with each 
mitoribosome carrying only one of the S18 family proteins. [50] However, Greber et al 
showed that each S18 protein occupies a distinct position in mitoribosomes and that the three 
S18 proteins can be present in one mitoribosome [41]. The S18-1 binds to the same site as 
bacterial S18, while S18-2 occupies another site in the SSU. S18-3 localizes to the LSU and 
not to the SSU which was previously believed to be present on SSU [35, 51]. All three 
mitochondrial S18 homologs possess zinc-binding motifs. However, one of the zinc-
coordinating cysteine residues is missing in both, S18-1 and S18-3. It is provided by MRPS6 
and MRPL10 in trans, respectively. In case of S18-2, all zinc-binding cysteine residues are 
contributed by one protein chain, however only two of these residues form a typical CXXC-
motif, while the third and fourth zinc-coordinating residues are distant in sequence. These 
unusual interactions involving two protein chains to coordinate the common zinc ion are 
probably needed for maintenance of quaternary structure and stabilization of MRPs. In 
mammalian mitoribosome, three of such interactions occur twice in case of S18 homologs, 
and one in MRPS25, where MRPS16 contributes the fourth zinc binding residue [35]. 
1.2 MITOCHONDRIAL RIBOSOMAL PROTEINS IN DISEASES 
Recent advances have revealed an important aspect that some of the proteins from SSU 
appeared to be multifunctional and they perform extra-mitoribosomal functions. For example, 
the protein sequence of MRPS29 shows similarity with the death-associated protein 3 
(DAP3), which is involved in apoptosis [52, 53]. It is not obvious whether its role as DAP3 is 
independent or employed as part of the ribosomal structure. 
1.2.1 Developmental and neurodegenerative disorders 
Differential expression pattern of MRPS6 has been shown in Down's syndrome (DS) and 
Parkinson’s disease (PS) mouse models. The DS is characterized by chr 21 trisomy [54]. 
Many clinical symptoms are associated with DS that differ in severity as well as prevalence 
among patients. Such symptoms include defects in neurogenesis, mental retardation, and also 
alterations in neuronal differentiation in the brain that results in earlier onset of Alzheimer's 
disease. 
Expression profile of mouse ESCs carrying human chromosome 21 (hChr21) showed an 
altered expression of S18-3 in the late differentiation of neurons [55]. The expression level of 
Mrps6 was higher in mouse model of DS (Ts65Dn) [56]. The gene expression analysis of 
cerebral cortex, cerebellum and hippocampus of another DS mouse model Ts1Cje was 
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assessed. Ts1Cje harbors a triplicated chromosome 16, partially, homolog of human 
chromosome 21. The study reported that Mrps6 was one of the genes with altered expression 
in brain [57]. 
 
Figure 3: The localization of MRPs in three distinct regions of SSU. The MRPs in circle are 
reported in different diseases. S18-2 is denoted in green circle. Figure was drawn using 
Chem Biodraw software. 
The differential expression of MRPS6 along with other genes was found in PD, marking it a 
putative candidate for PD [58]. Similarly, array comparative genomic hybridization analysis 
indicated loss of MRPS9 gene in sample isolated from a boy who showed intellectual 
disability and dysmorphic features [59]. 
1.2.2 Mitochondrial respiratory chain diseases 
As mentioned above, the mtDNA encodes 13 proteins that are involved in the process of 
OXPHOS. Several mutations in genes encoded by mtDNA are associated with diseases, for 
example, the Leigh syndrome (mutation in genes of complex I); the cardiomayopathy 
Kearns-Sayre syndrome and hereditary paraganglioma (mutations in the genes encoding 
complex II); optic atrophy, hypertrophic, cerebellar ataxia and encephalomyopathies 
(mutation in the genes encoding Complex IV); Luft’s disease (probably due to dysregulation 
of complex V) and undefined myopathies (due to a mutation in Coenzyme Q10) [60]. 
Mutations in the genes, encoding MRPs also cause severe respiratory chain dysfunction. A 
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homozygous nonsense mutation (Arg111Stop) in the MRPS16 led to a significant decrease in 
the activity of complex I and IV [61].  
Mutation in the MRPS22 gene was observed in case of Cornelia de Lange-like disease. The 
genetic cause of this disease is substitution mutation at Leu215Pro in the MRPS22 protein 
sequence that was detected in patient fibroblasts. Importantly, transfection of those cells with 
normal MRPS22 cDNA reverted the phenotype [62]. Another missense mutation 
(Arg170His) in the MRPS22 protein sequence was found in patient with mitochondrial 
dysfunction. Subsequent transfection of the patient cells with wild-type MRPS22 cDNA 
increased the 12s rRNA transcript level and normalized the enzymatic activities [63]. Also, in 
case of lactic acidosis the homozygous mutation of MRPS22 gene was found [64].  
Functional analysis of patient fibroblasts carrying mutated MRPS16 or MRPS22, was 
performed to find their impact on the integrity of SSU and LSU. Noteworthy, the low 
expression of MRPS16 also affected the levels of MRPS11 with inappropriate assembly of 
mitoribosome. However, the levels of MRPS16 had no effect on the LSU, limiting the effect 
to the SSU of mitoribosome. The retrieved mitoribosomes that harbor mutation (Arg170His) 
in the MRPS22 protein sequence contained less MRPS16 and MRPS11 [65]. In respiratory 
chain dysfunction other mutation, namely (Met184Val) in the MRPS7 protein sequence was 
implicated [66]. Mouse carrying a mutation in Mrps34 gene showed similar characteristics 
[67].  
1.2.3 Cardiovascular disease 
Mitochondria supply more than 90% of ATP required for the physiological function of heart 
and they play an important role during ischemia/reperfusion injury. 
The polymorphism of KCNE2 and SLC5A3/MRPS6 genes was found to be associated with 
high mortality of myocardial infarction in the Polish population [68]. The same single 
nucleotide polymorphisms (SNP) of the MRPS6 loci along with other 8 loci were identified in 
a large cohort study [69]. Mutation of Mrps33 was found in a minute syndrome of D. 
melanogaster [70]. MRPS10 appeared as one of the three crucial factors for better response to 
β-blocker therapy [71]. To identify the loci responsible for a high blood pressure 
susceptibility, genome wide analysis was carried out in obese adolescents, revealing 
association of MRPS22 loci with the high blood pressure [72]. 
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1.2.4 Cancer 
The overall theme of this doctoral thesis is to study the role of S18-2 in cancer. Apart from 
previous findings of our laboratory, others have demonstrated that S18-2 is expressed at 
significantly higher levels in tumor stroma and stroma of recurrent breast cancer [73] and 
other types of cancer as shown in Figure 4. The S18-3 was also expressed at high levels in 
breast cancer in a study carried out by selecting phage antibody libraries on breast tissue 
sections [74]. 
 
Figure 4: The mRNA expression levels of S18-2 in different cancers. Figure was adopted 
from [75].  
The association of defective versions of several MRPs have been reported with increased risk 
of cancer development (Table 1). For instance, amplification of MRPS23 gene was associated 
with increased proliferation in luminal type of breast cancer [76]. While, SNP of MRPS30 
genomic region were identified to be correlated with increased risk of postmenopausal breast 
cancer [77-81]. 
1.3 AN OVERVIEW OF CANCER 
Tumorigenesis is a multistep process encompassing genetic modification that drive the 
successful transformation of normal cells into aggressive malignant tumor cells [82]. The 
genetic and epigenetic changes that are commonly associated with most of the cancer types 
may be grouped into ten essential characteristics, designated as hallmarks of cancer. Such 
traits include independency on external growth signals, avoiding growth inhibitory signals, 
escaping apoptosis, immortal replicative potential, angiogenesis, metastasis and tissue 
invasion, immune evasion, metabolic dysregulation, tumor-promoting inflammation and 
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chromosomal instability [83, 84]. When these hallmarks are acquired as physiological 
capabilities, they collectively dictate malignant growth. The hallmarks of cancer may provide 
a guideline for future therapies targeting cancer [85]. In this doctoral thesis, I describe in 
detail the involvement of S18-2 in at least four features of cancer - immortalization, 
metastasis, genomic instability and cellular differentiation (see Figure 6). 
1.3.1 Oncogenes and Tumor suppressor genes 
Cancer cells differ from their normal counterpart in many physiological aspects, such as 
morphology, gene expression pattern and intercellular interactions, growth control and 
structure of cytoskeleton. With respect to gene expression two major classes of gene play 
important role in cancerogenesis - the oncogenes and the tumor suppressor genes (TSGs). 
The corresponding proteins regulate cell growth and proliferation; mutations and aberrant 
expressions of such genes induce tumorigenesis. Most of the cancer harbour mutations, 
deletions or promoter methylation of TSGs that leads to inactivation of TSGs, controlling cell 
cycle. On the other hand, gain of function by mutations or chromosomal rearrangement make 
oncoproteins constitutively active. Proto-oncogenes were discovered in carcinogenic 
retroviruses. The oncoproteins deliver excessive and uncontrolled growth promoting signals 
to cancer cells; few examples of well-known proto-oncogenes are Myc, Ras and Src. A 
striking difference between oncogenes and TSGs is that oncogenes act dominantly while the 
TSGs operate in recessive manner i.e. both alleles of the TSG must be mutated, deleted or 
inactivated to induce cancer. Retinoblastoma susceptibility (RB1) gene, p16 and p53 
represent TSGs that are inactivated in many tumor types [86]. 
1.3.2 Cell immortalization 
Normal human cells are endowed with an ability to replicate only a certain number of times. 
Normal cell populations cease proliferation when they have exhausted their allotment of 
permitted doublings and even enter apoptosis [87]. However, such limited proliferation 
conflicts with fundamental characteristics of cancer cells. During the period of development 
of neoplastic growth, human cells go through multiple successive growth and division cycles. 
Provided with proper nutrients, these cells may show unlimited replicative potential in culture 
and are thus said to be immortal. It is estimated that the adult human body comprises of 
approximately 3.72 × 1013 cells [88] and the organism as a whole undergoes at least 1016 cell 
division during its life-time [89]. Normal cells in general undergo approximately 50 
population doubling, what separates them from multipotent cells in early embryogenesis. 
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Table 1. The differential expression of MRPs genes in cancer. The data was adopted from 
[42] where authors in turn extracted information from the Oncomine database. 
 
Leonard Hayflick demonstrated in the 1960s that cultured cells isolated from human or 
rodents stopped further growth after certain number of divisions. Those cells enter into a state 
of so called replicative senescence, once achieving the expected number of replicative growth 
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cycle [90, 91]. Senescent cells might be metabolically active but they lose their ability of 
replication [92]. 
During the G2 phase of the cell cycle, ends of the long arms of two sister chromatids are fused 
together. Once the cell cycle enters the M phase (interphase), the spindle fiber binds to the 
centromere and pulls apart the two sister chromatids in opposite directions, unaware that the 
chromatids are joined at the ends of long arms [93]. The end to end fused arms should be 
separated cleanly. Otherwise the chromosome breakage could occur at weak points of 
chromatids [94].  
Telomeres are small tandem repeats of hexanucleotide sequence (5-TTAGGG-3) [95] present 
at the end of chromosome [96]. In immortalized and transformed cells the telomeres are 
continuously added to the end of chromosome by telomerase (hTERT) [97]. The hTERT is a 
complex of two subunits; a catalytic holoenzyme and the RNA. The catalytic subunit has 
reverse transcriptase activity [98] and uses its accompanying RNA subunit [99] as a template 
to synthesize the telomeric DNA. The length of telomeres determines the number of division 
of a cell. In normal cells after each replicative cycle telomere is shortened in the length, it 
becomes too short after certain number of cell cycles that it is unable to protect the 
chromosome anymore [100]. In that case the cells undergo crisis and consequently dies [101]. 
1.3.3 Migration and metastasis 
The spreading process of cancer is termed ‘‘metastasis’’ and is the major cause of tumor 
progression and patient’s death [102]. During metastasis the tumor cells behave 
autonomously [103] and do not respect their usual boundaries; therefore, cells may migrate 
and invade other parts of the body. Metastasis can be local when the tumor spreads to another 
area of the same organ or it could be distant. In the latter case the malignant cells enter the 
blood flow or lymphatic system and reside to other tissues or organs of the body. In order to 
gain the migratory and invasive ability carcinoma cells must undergo the process of epithelial 
to mesenchymal transition (EMT) to shed most of their epithelial phenotype [104]. During 
this process tumor cells growth pattern resembles to wound healing mechanism where the 
same phenomenon of EMT occurs. Under embryogenesis, during one stage of gastrulation 
the cells from ectoderm also migrate inside towards the centre to form mesoderm [105]. EMT 
is characterized by loss of expression of the epithelial markers E-cadherin [106, 107] and 
certain cytokeratins, and the gain of mesenchymal marker expression like vimentin, N-
cadherin and fibronectin [108]. E-Cadherin enables epithelial cells to attach one another by 
forming homodimeric bridges between adjacent cells. The ectodomain of E-cadherin extends 
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from plasma membrane of one epithelial cell and make a complex with other E- cadherin 
molecule, protruding from the surface of an adjacent cell [109]. Once the tumor cells arrive to 
new site, they regain their epithelial phenotype by reversing the EMT through the mechanism 
of mesenchymal to epithelial transition (MET) [110]. 
1.3.4 Cell stemness and differentiation 
Stem cells (SCs) are pluripotent cells that exhibit two distinctive characteristics: first the 
ability to maintain self-renewal and second the potential of differentiation into specialized 
cell lineages. In mammals, normally two types of SCs are identified. The first type is 
represented by the pluripotent embryonic stem cells (ESCs), existing in inner cell mass of 
blastocyst which can differentiate into any kind of somatic cells. The second type of SCs are 
adult stem cells that are reside in most of tissues and are believed as a part of repair system to 
replace damaged cells of the tissues. Highly organized and regulated signaling systems 
control the two fundamental characteristics of SCs, such as self-renewal and differentitation. 
Under normal physiologic conditions, controlled shifts in balance of such signaling pathways 
induce differentiation. Abnormalities in signaling cascades can initiate and promote cellular 
transformation and oncogenesis [111]. Apart from normal cells, cancer cells are also believed 
to arise from a population of cells that show SCs like properties called cancer stem cells 
(CSCs) [112]. Concept of CSC in maintenance of cancer cells was put forwarded few 
decades ago and has attracted great interest but remains controversial [113].  
Induced pluripotent stem cells (iPSC) are also a type of SCs that are generated in vitro from 
reprograming of differentiated adult cells. The first iPSCs were produced in 2006 by 
introduction of four transcription factors namely C-Myc Oct4, Nanog and Sox2 [114]. Several 
other genes have been identified that are associated with pluripotency of SCs, such as Klf4, 
Nac1, Essrb, Sall4, Tcl1, Dax1, Tbx3, Zfp281 and Rif1 [115-117]. Proteins encoded by 
pluripotency associated genes modulate the activity of each other to form transcriptionally 
regulated complex networks in ESCs [118]. 
The SCs divide in asymmetric manner giving rise to two progeny cells with different cellular 
fates. One of the daughter cells retains its identity as SC, other proceeds to spawn a 
population of transit amplifying cells that terminally differentiate to mature cells. It has been 
proposed that during the asymmetric division of SCs, the daughter cell that remain in SCs 
compartment receive both the parental DNA strands while the newly synthesized DNA strand 
are allocated to the other daughter cell who is destined for differentiation [119]. It is believed 
that SCs adopt such strategy to protect its genome from genetic damage. Each time cell 
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passes through S phase, DNA polymerase makes mistake during the replication that escape 
from repair mechanism. Consequently, the parental strand that are not synthesized during the 
most recent cycle of DNA synthesis are more likely to preserve wild type sequences than are 
those strands that are the product of recent DNA replication [119]. 
In this thesis, prostate, endometrial and colon cancer are used as models to show the status of 
S18-2 in tumors. 
1.3.5 Prostate cancer 
Prostate cancer (PCa) is the most frequently diagnosed cancer in men. According to Swedish 
national board of health and welfare database (Socialstyrelsen), 10 440 men were diagnosed 
with PCa and 2 357 PCa related deaths were recorded in Sweden in 2015 (Available at: 
http://www.socialstyrelsen.se/statistik/statistikefteramne/cancer). 
 The development of prostate starts as an outgrowth of epithelial buds in the urogenital sinus 
in late embryogenesis (embryonic day 17.5 in mice) [120] These buds rapidly extend and 
undergo morphogenesis of branching under the influence of androgen, resulting in the 
formation of a glandular architecture of prostate. The initial organ outgrowth continues 
vigorously after birth and it is largely completed before reaching sexual maturity. In contrast, 
the gland becomes mainly quiescent in adult, with very few cells displaying either mitotic cell 
divisions or apoptotic cell death [121]. The male testosterone hormone plays an important 
role during prostate initiation [122]. In adult prostate, the loss of androgen signaling results in 
rapid death of the majority of luminal epithelial cells, which express high levels of androgen 
receptor and require androgen signaling for their morphogenetic development, survival and 
maintenance [123, 124].  
Prostate cancer is the malignancy of prostate epithelial cells. Since 1986, early diagnosis and 
management of PCa has been developed, when tests for measuring Prostate-specific antigen 
(PSA) levels in serum were introduced into clinical routines. The PSA protein is produced by 
normal prostate cells at low levels. PSA levels in patient’s serum increases with enlargement 
of prostate, that may be a sign of prostate cancer [125]. However, similar changes in the PSA 
levels are also characteristic for patients with benign prostatic hyperplasia [126] and with 
acute bacterial prostatitis. 
In 2012, it was suggested that PCa screening based on PSA levels should not be used due to 
high rates of false-positive [127]. Despite this, one-third of men aged 65 years and older were 
screened in 2013 for PSA levels [128].  
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Most PCa–related deaths are due to the advanced metastatic stage of the disease that can 
spread locally or distantly to lymph nodes and bones. The mechanisms underlying PCa 
metastasis are incompletely understood both at the cellular and molecular levels [129].  
Gleason system evaluates the PCa growth pattern based on the microscopic analysis of 
surgical section of prostate specimen. The more PCa tissue differs in morphology from 
normal prostate tissue, the more severe is cancer. The prostate tissue samples are graded from 
3 to 5, with 3 as the least serious and 5 as the most serious degree of PCa [130]. 
The severity of PCa can be reduced using hormone therapy. The PCa cells even those that 
metastasized beyond the prostate gland need testosterone to grow. Therefore, the severity of 
PCa at all stages can be reduced by preventing the production of testosterone in body. 
Hormone therapy involves different strategies for blocking of testosterone synthesis like; 
surgical castration, medical castration (inhibiting testosterone production through drugs), 
administration of estrogen and anti-androgenic drugs. If patients are unresponsive to 
hormonal therapy then other procedures are applied such as chemotherapy, radiation and 
isotope treatment. 
1.3.6 Endometrial cancer 
Endometrial (uterine) cancer is initiated in the layer of cells that form the lining 
(endometrium) of the uterus. Between 2005 to 2015, each year about 1400 new cases of EC 
were reported in Sweden (Socialstyrelsen). The disease is rare before the age of 40 and older 
women are primarily affected by EC.  
The estrogen and progesterone are produced by ovaries. Normally, these two hormones are in 
balance to each other. However, an imbalance towards more estrogen increases a woman's 
risk for developing EC. The factors that influence hormonal levels include taking estrogen, 
tamoxifen and birth control pills, the number of menstrual cycles (over a lifetime), pregnancy 
and a number of births, obesity and also polycystic ovarian syndrome. This increases the risk 
of EC occurrence. Other risk factors are diabetes, high fat diet, age, family history and other 
type of cancer. 
The signs and symptoms of EC involve unusual vaginal bleeding, spotting and pelvic pain 
with weight loss. The diagnosis of EC is based on microscope examination which is possible 
only when tissue sections are isolated from patients. Currently, two systems are used for EC 
surgical staging - International federation of gynecology and obstetrics (FIGO) and American 
joint committee on cancer (AJCC). Both these systems are based on the TNM: tumor extent 
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(T), spread to lymph node (N) and distant sites (M). Usually surgery, chemotherapy, 
hormonal and radio-therapy are used to treat women with EC. 
There are two types of EC. The type 1 is morphologically classified as endometrioid 
carcinoma. The type 1 accounts for 80% of all the EC cases and affects both pre- and post-
menopausal women. Type 2 is morphologically clear cell or serous carcinoma and affects 
postmenopausal older women, as a rule. Type 2 are often poorly differentiated and have a 
worse prognosis, it develops directly from the endometrium without occurrence of 
hyperplasia. Type 1 is characterized by several genetic changes, but mutations in the tumor 
suppressor gene PTEN is most frequently observed. The mutations in PTEN are observed in 
up to 55% of precancerous endometrial lesions and 83% of EC [131, 132]. 
1.3.7 Colon cancer 
Colon adenocarcinoma (CRC) is the most common type of gastrointestinal cancer. Colorectal 
cancer is the third most common cancer after breast and prostate cancer in the world. In 
Sweden, 4 490 new cases of colon cancer were detected, including 2 222 men and 2 268 
women during 2015 (Socialstyrelsen). The statistics indicates that the incidence of CRC is 
equal in men and women. The risk of CRC increases with age. The etiology of CRC includes 
many factors, such as genetic and epigenetic alterations, environmental exposures (including 
diet) and inflammation of digestive tract. The common clinical symptoms associated with 
CRC include rectal bleeding, iron-deficiency anemia, abdominal pain and intestinal 
obstruction or perforation. In 2006, it was decided to introduce an organized CRC screening 
program in Sweden (Stockholm) [133]. The Council of the European Union issued 
recommendations in 2003 for FOBT based CRC screening in men and women aged 50–74 
[134]. Colon cancer is often detected during screening; other procedures of diagnosis are 
colonoscopy, sigmoidoscopy, biopsy of suspicious lesions and double-contrast barium 
enema.  
A genetic model for colorectal tumorigenesis called ‘‘Vogelgram’’ was proposed in 1990 by 
Eric Fearon and Bert Vogelstein. The model describes key genetic and epigenetic events at 
different stages of colorectal carcinoma, namely loss of chromosome 5q, 12p, 18q and 17p, 
and mutations of APC, KRAS, DCC, and p53 genes that were mapped in sequential order of 
cancer progression [135]. Later on, others found that mutation in BRAF, KRAS, 
PIK3CA genes and loss of heterozygosity of chromosome 18q are commonly associated with 
CRC incidence. Several studies identified genetic and epigenetic biomarkers in plasma for 
CRC detection. The overall specificity of such biomarkers up to 96% with sensitivity ranges 
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from 30% to 87%. [136]. The CRC are also divided in different stages on the basis of TNM 
classification. 
RB PROTEIN AND ITS ROLE IN CANCEROGENESIS 
1.3.8 Cell cycle and RB 
Most normal cell in body need external signals, such as those transmitted by mitogenic 
growth factors before they will decide to grow and proliferate [137]. Only early embryonic 
cells are exempt to this rule; they are able to multiply without receiving growth-stimulating 
signals. Since normal cells take part in the formation of precisely structured tissues their 
proliferation must be coordinated with adjacent cells in tissues. The body cannot give 
permission to each of its almost 10
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 cells to decide on its own to divide and grow, such 
scenario might create chaos [89]. Therefore, in a tissue the fate of normal cells is governed 
through cell cycle clock which make decision based on the wide variety of incoming signals. 
The cell cycle that operates in the nucleus of cells includes mechanisms that control the 
timing and rate of DNA duplication with cell division.  
The period between successive divisions of a cell is defined as the cell cycle, contents of the 
cell must be accurately replicated during this period. In 1950s, Alma Howard and Stephen 
Pelc observed in the broad bean, (Vicia faba) that DNA replication took place only at a 
specific phase of the cell cycle and that this stage was clearly separated from mitosis [138, 
139]. Based on these observations, other investigators identified the four characteristic phases 
of the cell cycle: G1, S, G2 and M phase [140, 141]. The DNA replication is deferred for 
approximately 12-15 hours between the birth of new daughter cells and subsequent DNA 
synthesis. This period of cell cycle is called G1 (first gap) [89, 142]. The decision about 
growth and quiescence is made by cells during a specific period in the G1 phase [143]. 
Evidences indicate that cells consult their growth-regulating signals during a distinct window 
of time in the active cell cycle: from the onset of G1 phase through most of G1, ending an 
hour or two i.e. 80-90% of G1 phase [144]. The cultured cells failed to precede the cell cycle 
when external growth promoting factors are removed before they reached the decision 
making 80-90% of G1 phase [143]. However, once the cells passed through the restriction 
point (termed R point) and advanced into the final portion of G1 (last 10-20% of G1) the 
elimination of growth promoting factors has no longer effect on their progress [137]. Then 
they can proceed through the remaining G1 and thereafter complete all the phases of cell 
cycle [89, 143]. 
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The G1 phase is followed by DNA synthesis phase termed as S-phase of the cell cycle that 
often requires 6 to 8 hours to reach completion in many mammalian cultured cells [89, 145]. 
The actual length of S phase varies greatly among different type of cells; it might be much 
shorter in rapidly dividing embryonic cells and lymphocytes. 
After S phase, a cell might enter directly to mitosis (M phase). However, most mammalian 
cells postpone their entrance into M phase, staying 3 to 5 hours in a second gap period, 
named G2 phase before they proceed to M stage [89, 145]. During G2, the cell prepares itself 
for admission into M phase and cell division. The M phase itself takes about an hour and it 
includes four distinct subphases of karyokinesis; prophase, metaphase, anaphase and 
telophase [89, 145]. An overview of cell cycle is graphically represented in Figure 5. 
 
Figure 5: Representation of four stages of cell cycle. The G1 black, orange the G1 phase 
after R point, S phase red, G2 phase green and M phase in blue color. The corresponding 
CDKs in complex with cyclin are shown. Figure was drawn using Chem Biodraw.  
The explanation of how R point transition is precisely executed remained unclear until the 
first tumor suppressor gene, the retinoblastoma susceptibility (RB1) gene was identified and 
isolated by positional cloning during the mid-1980s [146-149]. Alteration in RB1 gene was 
found to be associated with pathogenesis of retinoblastoma, sarcomas [146], glioblastomas 
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[150], small-cell lung [151], bladder [152], breast [153], cervical [154] and parathyroid 
cancers [155], supporting the idea that the gene and the translated protein is involved in a 
tumor suppressing pathway. The human retinoblastoma gene RB1 is a prototype of tumor 
suppressor genes [156]. The cloning of the RB1 gene and determination of homozygous RB1 
mutations in retinoblastoma follow the Knudson (1971) model, which states that a tumor 
phenotype appears only when both copies of the gene are altered [157]. The heritable form of 
retinoblastoma is caused by deletion of RB1 usually, in that case the appearance of retinal 
tumors occurs with an incidence of more than 95% [158]. Importantly, the retinoblastoma is 
mostly a childhood cancer. The cause of retinoblastoma in a specific age period indicates a 
model of tumor initiation in which loss of RB function must happen in certain populations of 
cells that may be transiently exist in the retina of developing eye [159].  
1.3.9 Gene and protein family of RB 
The RB1 gene is comprised of 27 exons spanning approximately 180-kb of genomic DNA on 
human chromosome 13q14. The locus transcribes a 4.7-kb transcript that encodes a nuclear 
phosphoprotein consisting of 928 amino acids, the retinoblastoma protein (RB/p105) [160]. 
Two RB related proteins also exist, the p107 and RB2/p130 that are located on human 
chromosome 20q11.2 and 16p12.2, respectively [157].  
During cell transformation, viral oncoproteins target the RB family proteins [161, 162]. The 
sequences specific for binding to oncoproteins are called “pocket” which is common among 
three RB proteins, hence these proteins are often termed pocket proteins. Structurally, the 
pocket domain contains two conserved functional domains (A and B) that are separated by a 
spacer (S) sequence. The spacer is substantially different between the three RB proteins. The 
presence of a motif with LxCxE sequence is usually characteristic feature of proteins that 
target RB family proteins. A tridimensional LxCxE-binding site is located in the B-domain of 
pocket region of RB proteins. Several RB targeting viral oncoproteins have been identified, 
for example, early-region 1A (E1A) of the human adenovirus that carry the LxCxE motif 
[163]. The E7 protein from a high-risk human papilloma virus consists of three functional 
domains: the CR1 and CR2 in the N-terminus, and a large zinc-finger domain in the C-
terminus. The CR2 sequence contains the LxCxE motif for binding to RB pocket proteins 
[164]. The large T antigen of polyomaviruses like simian virus 40, JC and BK viruses also 
possess LxCxE motif that target the RB proteins [165]. Herpes viruses developed more 
sophisticate way to target the RB-E2F pathway. For example, EBV-encoded nuclear antigen 
6 (EBNA-6) inactivates RB by binding with the S18-2 protein, that serves as a bridge 
between EBNA-6 and RB [166]. The consequence of such binding is the inactivation of RB 
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proteins and transactivation of responsive genes, required for inducing the progression of cell 
cycle [163]. The targeting of RB protein by viral oncoprotein paved the way for the 
understanding of TSGs. 
The RB2/p130 and p107 are closely resembled each other, sharing about 50% amino-acid 
sequence identity, compared to RB/p105 (approximately 30-35% identity). Noteworthy, 
mutations in p130 and p107 are not common in human cancers [167]  
1.3.10 Mechanism of action of RB 
The retinoblastoma protein is broadly studied for its role in the regulation of cell cycle. RB 
directly binds the transcription factor (TF) E2F1. This binding leads to inhibition of 
transcriptional activity of E2F1, and it remains inactive during the G0 and M phase of cell 
cycle [137]. Phosphorylated state of RB cannot interact with E2F1 but RB binds and 
inactivates E2F1 when it is unphosphorylated. RB is mostly unphosphorylated when the cells 
are in G0 phase. It becomes weakly phosphorylated (hypophosphorylated) at specific serine 
and threonine residues during the first 80-90% of G1 phase, while it is extensively 
phosphorylated (hyperphosphorylated) at R point gate, thereafter, RB remains 
hyperphosphorylated throughout the cell cycle [157, 168]. 
The phosphorylation of RB is controlled through cyclin dependent kinases (CDKs) [169]. 
The CDK4 and CDK6 are growth signal dependent CDKs that operate during first 80-90% of 
G1 phase while growth signal independent CDKs (CDK1, 2 and 3) are active in the rest of 
cell cycle [89] [170]. CDKs need cyclin molecules (Cyclin D, E and A) as a guide for 
phosphorylation of RB according to the requirement of cell cycle at different stages [171] 
[172]. Apart from cyclins, cells also employ CDKs inhibitors to regulate the activity of CDKs 
and thus inhibit phosphorylation of RB [171, 173]. CDK inhibitors are classified into two 
categories; p16INK4A, p15INK4B p18INK4C and p19INK4D inhibitors of CDK4/6 [174] 
and p21Cip1, p27Kip1 and p57 Kip2 for inhibition of CDK1, 2 and 3[175].  
The inactivation of RB led to uncontrolled cell division that might result in development of 
cancer. Cancer cells adopt different strategies for inactivation of RB such as mutation and/or 
deletion of RB1 gene, epigenetic silencing of RB1 gene expression, inactivation of CDK 
inhibitors, mutation in CDK genes and recruitment of certain proteins that binds RB and 
prevent its association to E2F1 [89]. 
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1.3.11 RB binding partners 
As mentioned above that oncoproteins target the RB protein to drive the cellular 
transformation. The literature review reveals that RB binds to 218 proteins; we have 
summarized the data for 27 of them which are important in cell stemness or cancer 
development. Apart from RB control over cell cycle through E2F1, RB can bind to other 
proteins which are indirectly involved in cell cycle like LIN9, DYRK1A, and S18-2 protein. 
Some RB-interacting proteins like ZBTB7A [176], SKI [177], EID1 [178], LDB1 [179] and 
PSMD10 [180] are involved in maintenance of pluripotency and self-renewal of SCs. HBP1 
[181], SPI1 [182], CEBPB [183], MYOD1 [184], CENPF [185], PELP1 [186] are also RB 
associated proteins that regulates lineage specific differentiation of cells. Yet other RB 
binding proteins like SIN3A [177] control proliferation through regulating the c-Myc level 
[187], TRAP1and PHB protect cells from apoptosis [188]. Many RB interacting proteins are 
involved in epigenetic regulation of gene expression for example; UHRF2 (DNA 
methylation) [189], HDAC (Histone deacetylase) [190], KDM5A (H3K4 demethylation) 
[191], SIRT1 (H4K16 acetylation) [192] and DNMT1 (DNA methylation) [193]. 
1.3.12 S18-2 and RB 
The S18-2 was initially cloned from hematopoietic SCs [194]. Working with Epstein-Bar 
virus (EBV), it was found in our laboratory that S18-2 formed a bridge between RB and EBV 
encoded nuclear antigen 6 (EBNA6). Evidences based on the results of yeast two hybrid 
system, GST pull down and surface plasmon resonance showed that S18-2 binds RB. The RB 
association to E2F1 was inhibited due to such binding, as the free E2F1 levels significantly 
increased in the nucleus of S18-2 overexpressed cells [166].  
The binding site of S18-2 in RB is not known yet but most probably it is present either in C-
terminus or middle region of RB protein, as S18-2 binding with RB was observed when a RB 
construct was used with deleted N-terminus. As mentioned above that overexpression of S18-
2 led to immortalization of rat embryonic fibroblasts (REFs). The S18-2 immortalized cells 
induced the expression of embryonic SCs markers like SOX2, OCT4, SSEA1, Nanog etc. 
[195].  
The gene expression analysis showed that more than 2000 genes were differential regulated 
with overexpression of S18-2 compared to primary REF. The upregulated genes were those 
involved in the transcription/translational machinery of redox reaction like elongation factors, 
ATP synthases, mitogen activated kinases, NADH dehydrogenases. The genes were involved 
in pathways which are characteristics of rapidly proliferating cells like P13K/AKT signalling, 
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pathways involved in the OXPHOS, ubiquinone (coenzyme Q10) biosynthesis and fatty acid 
elongation in mitochondria were upregulated. Cells immortalized by overexpression of S18-2 
produced more pyruvate, indicating enhanced ATP synthesis [196]. 
 
 
Figure 6: S18-2 and RB interaction. The graphical abstract of study. Figure shows that 
S18-2 binds to RB resulting in RB-E2F1 association. The study describes the effect of RB-
S18-2 in embryogenesis, stemness, cell migration, immortalization and advancement of 
cell cycle. 
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2 AIMS OF THE STUDY 
The overall aim of this doctoral thesis was to study the role of MRPS18-2 in cancerogenesis. 
Project specific aims are as follows: 
1. To trace the evolutionary history of the S18 family of mitoribosomal proteins. 
2. To characterize the terminally differentiated rat skin fibroblast transformed by S18-2. 
3. To identify the cumulative role of RB and S18-2 in control of cell stemness and 
differentiation. 
4. To demonstrate the status of S18-2 in human cancers, particularly colon, endometrial 
and prostate adenocarcinoma.  
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
Primary cultures of REFs have been used in many studies to demonstrate the effect of 
different oncogenes like Myc and Ras on cell transformation. A few years ago another 
exciting field drew the attention of scientific community when it was reported that MEFs 
could be transformed into iPSCs. The set of four genes that were initially used in MEF to 
establish iPSC from MEF, those genes were; SOX2, OCT4, KLF4, and c-Myc [197]. Later on, 
iPSCs were produced from rat and human cells by expressing different combinations of 
genes. Since then several genes have been identified that induced the SC phenotype in 
primary cells. 
It was shown previously in our laboratory that overexpression of S18-2 immortalized REFs 
[195]. The resulting cell line was termed 18IM. Expression of SC markers was observed in 
18IM cells while they lost mesodermal markers. Noteworthy, 18IM cells were originally 
established from fibroblasts isolated from rat embryos. Thus, a major critique about this work 
was that primary culture probably contained some SCs of embryos, exhibiting SCs like 
phenotype, even though all the experiments were performed in parallel with control 
experiments, namely transfections with the plasmids, encoding a mutated start codons of S18-
2. To clarify, S18-2 was overexpressed in terminally differentiated rat skin fibroblasts which 
were isolated from the skin of a mature rat. After selection with antibiotics different clones 
were isolated for further experiments. 
3.1.1 S18-2 transformed RSFs exhibit de-differentiated phenotype 
The iPSCs can develop teratomas and other kind of tumors in experimental animals [198]. 
Several genes and their products that induce pluripotency play pivotal roles in cell 
transformation and tumorigenesis. For instance, a fusion gene comprising between a portion 
of OCT4 and the gene encoding N-terminus of Ewing sarcoma (EWS), a product of the 
chromosomal translocation t(6;22)(p21;q12) is believed to be a putative oncogene in 
sarcomas [199]. The 3q26–27 locus that carries the SOX2 gene is usually amplified in solid 
tumors [200]. A high expression level of LIN28 is associated with epithelial ovarian cancers 
with poor prognosis [201] and embryonic carcinomas [202]. The LIN28 and KLF4 are also 
upregulated by N-Myc driven neuroblastomas [203]. 
Some of the clones of S18-2 immortalized RSFs also developed tumors when injected 
subcutaneously into SCID mice. RSFs were immortalized with GFP–S18-2 (clones 6, 13, and 
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17) and REFs were immortalized with pBabe–S18-2 (clones 2, 4, and 6) or GFP–S18-2 
(18IM and clones 12, 10). Tumors were observed in experimental animal after injecting RSF-
S18-2 clone 6 derived from RSFs. The tumors produced by REFs (clone 10) appeared after 
two months and with RSFs tumors were detected after three months post-injections. 
3.1.2 Ectopic expression of S18-2 disrupts the normal cell cycle distribution 
Stem cells have an abbreviated cell cycle with very short G1 phase (of 2.5 to 3 hours) 
compared to mature cells [204]. The BrdU incorporation assay was performed for cell cycle 
distribution analysis. The S phase content significantly varied between immortalized cells and 
REFs: a higher proportion of 18IM and REF-S18-2 clone 10 cells were found in S phase 
compared with primary REFs. Correspondingly, the proportion of these cells in G1 phase was 
reduced. In contrast, the proportions of immortalized and primary RSFs in S phase did not 
differ between cells. However, aneuploidy was observed in RSF-S18-2 clone 6, which was 
tumorigenic in SCID mice and a proportion of these cells had a DNA content of “8N”. The 
number of cells in G2/M was also significantly higher in RSF-S18-2 clone 6 cells than in 
control cells; this difference might reflect a tetraploid G1 population. 
3.1.3 S18-2 overexpression evokes chromosomal instability 
Evidence of aneuploidy was demonstrated by karyotyping of RSF-S18-2 clone 6 cells and 
compared with REFs transformed by overexpression of c-Myc and mutated Ras (H-Ras) 
genes as well as control RSFs.  
Normally, there are 20 chromosomes in rat cells and the karyotyping results indicated that 
control RSFs carry 20 chromosomes, c-Myc and H-Ras, transformed REF showed certain 
level of aberration but S18-2 overexpressed cells exhibited extremely high degree of 
chromosomal instability. This might explain the tumorigenic behavior of RSF-S18-2 clone 6 
in experimental animals. 
Previous studies reported that oncogenic transformation of REFs requires the cooperative 
activation of at least two oncogenes [205]. Later on it was shown that mutated Ras alone 
could induce the cell transformation despite its low expression in the resulting immortalized 
cells [206]. In same manner c-Myc alone could immortalize cells potently but the cells did not 
show characteristics of transformed cells [207]. In our study, we showed that overexpression 
of S18-2 alone is sufficient to transform cells, alter their cell cycle profiles, cause potential 
genomic instability and lead to the rise of tumors in an experimental animal model. 
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3.2 PAPER II 
It was obvious that S18-2 play an important role in cell transformation. The next aim was to 
elucidate how the whole family of S18 proteins arise during the course of evolution. For this 
purpose, the evolutionary history of the whole S18 family was traced using bioinformatics 
tools and publically open databases. In total 19 bacterial and 59 eukaryotic species that 
represent important clades were selected for the study. 
Homologs of the Homo sapiens S18 protein can be traced back to bacteria and they are 
present in all major species of cellular organisms. The consistent presence of S18 homologs 
in all major species of eukaryotes and bacteria indicates the functional importance and key 
role of S18 protein in cellular organisms. 
3.2.1 Domain architecture of S18 proteins 
The Ribosomal_S18 domain, a conserved sequence of approximately 152 amino acids exists 
in S18 proteins across all species. The domain architecture of bacterial S18 is diverse. In 
contrast, S18 proteins show single-domain architecture in eukaryotes. However, in S18-3 of 
catarrhini (old world monkeys, a group consisting of Macaca and Papio etc.) a lineage-
specific protein fusion event was observed. The S18-3 protein comprised of two domains, 
Ribosomal_S18 and GAT_1 (Type 1 glutamine amidotransferase-like). 
The conservation profile of S18 homologs suggested that despite long divergence times on 
the species tree, S18 orthologs are highly conserved (around 50% sequence identity on 
average) across bacterial species under investigation. Contrary, there are differences in the 
conservation profiles in metazoan S18 homologs. 
3.2.2 Specific gene duplication events gave rise to three homologs of S18 in 
metazoans  
Three rounds of duplication events have occurred in metazoan lineage; but one duplication 
disappeared in the branch leading to a parent of S18 of placozoa and eumetazoa. The first 
round of duplication resulted into S18-3 and the parent of S18-1 and S18-2. Another round of 
duplication took place to give rise to S18-1 and S18-2. In a recently analyzed structure of 
mammalian mitoribosome by Greber and co-workers, it was shown that S18-1 and S18-2 are 
present on small subunit while S18-3 binds to large subunit of mitoribosome [41]. The 
localization of S18 homologs also indicated that S18-3 was the product of an earlier gene 
duplication and became a part of LSU. Its sibling remained a part of SSU, where it underwent 
another gene duplication event to divide into S18-1 and S18-2. Furthermore, bacterial S18 
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shares the most sequence similarity with metazoan S18-1; this is in agreement to structural 
analysis which states that S18-1 occupies the position of its bacterial S18 homologs in the 
SSU [41]. 
3.2.3 The Gly132 polymorphism in S18-2  
Due to the crucial role played by S18-2 in cell immortalization it was important to analyze 
the mutational status of S18 family proteins with the focus on evolutionarily conserved amino 
acids. In addition, we compared these data with the mutations of other mitoribosomal proteins 
in cancer. For mutational analysis of whole 55S mitoribosomal proteins in biospecimens and 
different cancer cell lines, the data were extracted from COSMIC database. In the S18 family, 
S18-1 and S18-2 were found highly mutated proteins along with other MRPs. Other highly 
mutated proteins of mitoribosome were MRPL32, MRPL51, and MRPL55 from LSU, and 
MRPS14 and MRPS25 of SSU. Interestingly, the mutation of S18-2 at Gly132 was widely 
observed in colon carcinoma samples. Five out of six colon adenocarcinoma (CRC) biopsies 
and one of ovarian carcinoma biopsies mentioned in COSMIC carried Gly132 mutation in 
S18-2. 
To verify Gly132 mutation in S18-2 gene the DNA was amplified from both, normal and 
cancer tissues of CRC patients, using primers for wild-type and mutated DNA. Amplification 
was detected in DNA of both normal and tumor tissue with both mutated and wild type 
primer. For confirmation, the PCR products were sequenced that also supported the PCR 
analysis. The mutation resulted in substitution of Glycine to Cysteine at position 132. This 
suggests the presence of a polymorphism of S18-2 gene in CRC patients where one allele 
codes the Glycine and other allele codes for Cysteine. Detection by currently available 
technologies, 20% to 50% of CRC cases failed to show any mutations, although major genes 
for polyposis and nonpolyposis familial CRC have been identified. It is estimated that 
heredity is responsible for approximately one-third of the susceptibility to CRC [208], and 
that causative germ-line mutations account for less than 6% of all CRC cases [209]. 
Recent approaches used for the discovery of new cancer-associated genes are based on 
genome-wide technologies. Based on the International HapMap Project data, patterns of 
polymorphisms in candidate and other anonymous genes were identified that were spread 
throughout the genome [210]. 
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3.3 PAPER III 
For the first time the expression pattern of S18-2 was analyzed in cancer clinical specimen 
using endometrial cancer (EC) tissues from patients. The expression of S18-2 was analyzed 
in different grades of EC to evaluate the possible role of S18-2 in cancer. Samples were 
collected from women who underwent surgery at Karolinska University hospital. Based on 
the morphological features, ECs were graded according to the criteria of the 2009 
International Federation of Gynecology and Obstetrics (FIGO) [11]. Samples were divided 
into six groups; 1. highly differentiated adenocarcinoma (HDA), 2. moderately differentiated 
adenocarcinoma (MDA), 3. low differentiated adenocarcinoma (LDA), 4. serous cancers 
(SC); 5. hyperplasia (HP) and 6. normal epithelia (NE). In total 49 samples were analyzed. 
3.3.1 Expression of S18-2 protein was elevated in tumors  
The S18-2 signal was not detected in normal tissues and very weak signals were observed in 
hyperplasia. In comparison, tumor cells demonstrated strong cytoplasmic S18-2 signal. In 
LDA samples a proportion of cancerous cells showed nuclear signal of S18-2. However, the 
proportion of such expression was less than 3-5% of all tumor cells. The statistical analysis of 
the staining showed a significant difference in expression levels of S18-2 protein among the 
group of tumor samples and normal tissue, together with hyperplasia. Surprisingly more 
advanced endometrioid adenocarcinomas showed a tendency of decreased S18-2 signal. The 
C-terminus of E2F1 (residues 409-426) is involved in binding to the RB protein, Therefore, 
we employed a mouse monoclonal antibody directed against the C-terminus of E2F1 protein 
with hope that it could recognize only the E2F1 free from RB. The nuclear signal of free 
E2F1 was elevated in less differentiated tumors and it was significantly higher than in normal 
tissue and in hyperplasia. Noteworthy, the high E2F1 expression significantly correlated with 
highly expressed S18-2 in analyzed tumors. 
3.3.2 Ectopic expression of S18-2 is associated with EMT in EC cells  
Multinucleated cells were observed when S18-2 was overexpressed in different cancer cell 
lines such as breast cancer cell line MCF7 and kidney tumor cells KRC/Y [211]. To monitor 
the molecular effect of high expression of S18-2 on EC, a cell line of EC, HEC1-A was by 
transfecting a GFP vector expressing full length of S18-2 cDNA. With overexpression of 
S18-2 the expression of pan-keratin, cytokeratin 18, beta-catenin, and E-cadherin was 
decreased while vimentin was expressed more compared to parental cells. Such expression 
pattern of proteins indicates that cells underwent EMT upon overexpression of S18-2 that is 
associated with invasive ability of tumor cells. 
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3.3.3 Expression of S18-2 EC cells increased in vivo proliferation in 
experimental model 
Both parental and S18-2 overexpressing cells were injected subcutaneously into SCID mice, 
in order to characterize the tumorigenicity of these cells. Tumors were detected in all 
injection sites (4 for each cell line) but with different proliferation rates. All experimental 
animals were sacrificed at the same time, day 23, when the largest tumor was observed. 
Growth curves showed that compared to the control HEC-1-A cells, the sub-line that 
expressed S18-2 constitutively at the high levels proliferated faster.  
The expression pattern of S18-2 in EC clinical biospecimen, induction of EMT in EC cell and 
increased in vivo proliferation indicates the putative role of S18-2 in development of cancer. 
3.4 PAPER IV 
Prostate cancer was used as another model to study the role of S18-2 in tumorigenesis. As 
described several times, overexpression of S18-2 induced expression of SC markers. In this 
study the correlation between S18-2 and the SC marker CXCR4 was studied in PCa. The 
S18-2 expression was analyzed in 12 prostate clinical specimens with Gleason score more 
than 6 and compared with 11 control specimens. The neoplastic lesions in the PCa samples 
were highly positive for S18-2 while benign gland and hyperplastic sections were negative 
for S18-2 signals. CXCR4 expression was also analyzed in some of the PCa serial sections 
and it was found that S18-2 and CXCR4 were expressed in the same lesions.  
To study the molecular effect of S18-2, sublines of PCa cell line PC3 were generated with 
transfection of a pBabe vector carrying full length of S18-2 cDNA. After selection two clones 
were generated PC3-S18-2-CL03 and PC3-S18-2-CL04 where PC3-S18-2-CL04 cells 
expressed higher levels of S18-2 than PC3-S18-2-CL03.  
3.4.1 S18-2 overexpression induced EMT and motility in PCa cells 
The levels of EMT markers were correlated with the expression level of S18-2. E-cadherin 
was reduced significantly in PC3-S18-2-CL04, compared to PC3-S18-2-CL03 and PC3. The 
expression of cytokeratin 8 was also decreased in PC3-S18-2-CL04, in comparison to PC3-
S18-2-CL03 and PC3. Though beta catenin remained unchanged but expression of Pan-
keratin was lowered both in PC3-S18-2-CL03 and PC3-S18-2-CL04. Such expression pattern 
indicates that EMT was induced in PC3-S18-2-CL04 at a higher degree compared to PC3-
S18-2-CL03 and PC3. 
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The mRNA expression level of EMT related transcription factors was assessed, both with 
overexpression of S18-2 in PC3-S18-2-CL03 and in PC3-S18-2-CL04 as well as after 
downregulation of S18-2 in PC3. The expression levels were compared to those in the PC3  
Figure 7: The Figure depicts that S18-2 can enrich the CXCR4-CXCL12 axis that 
upregulates the TWIST2 repressing the E-cadherin expression. Consequently, the cells 
undergo EMT 
cells. There was no significant difference observed in the expression level of majority of 
thestudied genes, except for the TWIST2 gene. The relative expression level of TWIST2 
mRNA was tightly correlated with the expression level of S18-2 protein.  
To test the effect of S18-2 on the induction of EMT and migration of PCa cells, zebrafish 
embryos were used. The DII labeled PC3, PC3-S18-2-CL03 and PC3-S18-2-CL04 cells were 
injected in perivitelline space of 48 hours post fertilization (hpf). Interestingly, the number of 
PC3-S18-2-CL04 migrated cells was significantly higher compared with PC3-S18-2-CL03 
and original PC3 cells. The number of PC3-S18-2-CL03 migrated cells lie between the values 
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for PC3-S18-2-CL04 and original PC3 cells. To confirm the effect of S18-2 on the CXCR4-
driven migration of cells, S18-2 expression was decreased in the aggressive clone PC3-S18-
2-CL04 by transfection of S18-2 specific siRNA. This in turn dramatically decreased the   
CXCR4 dependent migration of resulting cells when compared to same cells transfected with 
control siRNA. 
3.4.2 CXCR4-CXCL12 axis 
Prostate cancer is the neoplasm of epithelial cells but the stroma cells of prostate are also 
important for the progression of cancer. Generally, the communication between stroma and 
tumor cells is mediated through cytokines and their receptors. The CXCL12-CXCR4 axis has 
been a subject of many studies devoted to characterization of different tumors. The TWIST 
genes are described as master genes of EMT and that TWIST2 expression is under control of 
the CXCR4-CXCL12 axis [212]. 
The PC3 cells already expresses CXCR4 at certain level. However, with the overexpression 
of S18-2, a slight but statistically significant increase in the CXCR4 expression was observed 
in PC3-S18-2-CL04 cells. While the signal of CXCR4 expression in the PC3-S18-2-CL03 
and in PC3 cells was almost similar. Following overnight starvation of the cells, the next day 
cells were treated with CXCL12. Significantly higher signal of migration was detected in 
PC3-S18-2-CL04 group, compared to PC3-S18-2-CL03 (p=0.093) and PC3 (p= 0.007). The 
number of cells that migrated in response to CXCL12 was in the same pattern as; the level of 
EMT makers, migration in zebrafish, mRNA level of EMT related TF, and the expression 
level of CXCR4. One of the effects of the CXCL12-CXCR4 axis in the migration of cancer 
cell is through increase of TWIST expression that is a repressor of E-cadherin. It was also 
observed in this study that S18-2 increased the CXCR4 expression and the cells underwent 
EMT. 
To further explore the CXCR4 mediated migration upon S18-2 overexpression, CXCR4 was 
masked in PC3-S18-2-CL04 by anti-CXCR4 antibody which also caused significant 
reduction in the CXCL12 directed migration of cells compared to same cells cultured with 
isotype control antibody. The migration was observed in zebrafish embryo model. 
3.4.3 Tumorigenesis of cells in experimental animals, SCID mice 
PC3 cells proliferate faster than PC3-S18-2-CL03 and PC3-S18-2-CL04 cells. The tumor 
initiation was similar for all the cells. However, after 6 weeks the PC3 cells develop larger 
tumors compared to tumors produced by PC3-S18-2-CL03 and PC3-S18-2-CL04 cells. This 
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indicates that all the three-cell type exhibit the same potential of giving rise to tumors but 
later on the proliferation of cells with overexpression of S18-2 was reduced. The tumors 
produced by PC3-S18-2-CL04 contained many foci and buds which is a strong indication of 
metastatic tumors with more migratory ability. 
These data suggest that S18-2 enriched the CXCL12-CXCR4 axis that upregulated the 
expression of TWIST2 which is a repressor of E-Cadherin. Consequently, due to the loss of 
E-Cadherin, cells underwent EMT and gained the ability to migrate more with 
overexpression of S18-2, as presented in Figure 7. 
3.5 PAPER V 
The Retinoblastoma protein controls cellular fate through governing physiological processes 
like cell proliferation and differentiation. Previous studies showed that RB exists mainly in 
the inactive phosphorylated form while only small traces of active RB are present in the 
nucleus of ESCs [213]. Beyond the direct control of RB in the transcription of genes through 
E2F1, it can also interact with chromatin remodeling enzymes. Such interactions of RB may 
be important for its ability to regulate the global genes expression, including the genes 
involved in cell stemness and differentiation [190, 214-218]. Based on the fact that there is a 
strong correlation between cancer and the differentiation state of cells and that S18-2 is a RB 
interacting protein that induces the expression of SC marker, we studied the cumulative effect 
of overexpression of S18-2 in the presence and absence of RB with regards to maintenance of 
cell stemness and differentiation. For this purpose, fibroblasts isolated from mouse embryos 
that were homozygously knockout for RB1 gene were used. Three more sub lines were 
generated by transfection with different combinations of S18-2 and RB1. Firstly, the RB1 
knockout fibroblast (RH) were transfected with plasmid expressing the GFP-S18-2 fusion 
protein. The resulting immortalized cell line was named as RH18. Then, the RH and RH18 
cells were further transfected by a plasmid encoding the full-length RB. The individual clones 
produced by the transfected cells were analyzed for RB expression. Further work was 
performed on RH cells and 3 sub-lines: RH18 that expressed S18-2 at higher levels, RH18RB 
that expressed S18-2 in the presence of RB and RHRB where RB was reconstituted but with 
endogenous level of S18-2. 
The cells ectopically expressing S18-2 in the presence of RB attained a morphology 
resembling mouse ESCs in culture. Several colonies were observed in RH18RB cultures, 
some of the colonies were round but most of them were dome-shaped of rapidly growing 
cells with tight borders and close packing. 
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The S18-2 overexpressing cells lost smooth muscle actin (SMA) both in the presence and 
absence of RB. Most interestingly, with the overexpression of S18-2 the RB was localized 
both in the cytoplasm and nucleus of RH18RB cells as shown by immunofluorescence 
analysis. Cell fractionation following western blot analysis confirmed the presence of RB 
both in the cytoplasm and nucleus.  
3.5.1 Highly expressed S18-2 is sufficient to induce the telomerase activity 
Stem cells have prolonged proliferative ability; they should have a mechanism to stabilize the 
length of telomere through several cell divisions. The ESCs and undifferentiated embryonal 
carcinoma cells display high levels of hTERT expression and telomerase activity. Increased 
telomerase activity by overexpression of TERT improved self-renewal ability, proliferation 
and differentiation efficiency in ESCs [219]. The deficiency of telomerase activity was 
observed to be related to DNA methylation and histone deacetylation of TERT gene in 
differentiating ESCs [220]. Therefore; high levels of telomerase activity or the expression of 
TERT are believed to be a marker of pluripotent ES cells [221]. 
High telomerase activity was associated with overexpression of S18-2 in RH18 and RH18RB 
cells. The expression of RB with endogenous levels of S18-2 in RHRB cells resulted in 
marked decrease of telomerase activity. It has been shown that replicative senescence is 
linked to the RB and its interacting partners. Indeed, activation of both the p53 and 
p16INK4A–RB pathways are important for the induction of senescence in a variety of human 
cancers [222]. Regardless of RB expression the overexpression of S18-2 enhanced the 
telomerase activity that is an important prerequisite for the proliferation of SCs. 
3.5.2 S18-2 overexpressed cells with reconstituted RB behave like SCs  
The RT
2
 profiler array is a qPCR based efficient approach to study the expression pattern of 
genes involved in different cellular processes. The mRNA expression level of 84 genes, 
specific for mouse ESCs in the four cell types were assessed. The genes represented: ESC 
markers, chromatin modification and remodeling factors, transcriptional regulators, 
transcription factors, markers of pluripotency, iPSC enhancers, markers of ectoderm, 
mesoderm and endoderm lineage, pre-adipocytes progenitor cell markers and specific 
markers of neural, cardiac, early smooth muscle, early endothelial, hematopoietic and 
mesenchymal SCs. 
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Most of the mouse ESC related genes were up regulated in RH18RB cells compared to the 
other three cell types. Noteworthy, the Gata-1 gene, was highly expressed in RH18RB cells 
compared to RH cells. Gata-1 is the marker specific for endothelial cells. 
Figure 8: S18-2 binds RNF2 while RB interacts with RING1, the interaction between S18-
2and RB bring RNF2 and its adopter RING1 in close proximity, leading to increased activity 
of RNF2. Consequently, histone H2A is highly monoubiquitinated at lysine 119 that 
maintains the SCs phenotype. 
The GATA-1 protein is essential for the development of megakaryocytic (platelet producing 
cell) and erythroid cells (red blood cell) [223]. It helps in transcription of the α-spectrin [224], 
an important structural protein of red blood cells. Interestingly, the GATA1 is an endothelial 
cell marker but the origin of RH18RB cells (which was originally MEF) is mesenchymal. It 
indicates that RH18RB cells demonstrate mesenchymal cells characteristics but might also 
show traits of the endodermal and ectodermal cell lineages. Another gene that was highly 
expressed in RH18RB cells was the Thy compared to RH cells. Thy1 or CD90 is a marker of 
HSC, Thy-1 has been postulated to be involved in cell adhesion, cellular recognition and T-
cell activation [225]. 
The expression of SOX2 and OCT4 was observed at protein level in S18-2 overexpressed 
cells. The expression levels of these markers were higher in RH18 cells than RH18RB. 
Presumably, in RH18RB culture due to presence of RB, a proportion of cells spontaneously 
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differentiated, while RH18 cells might lack the differentiation ability. The directed 
differentiation method is widely used to test the pluripotency of SCs in vitro. To study the 
role of highly expressed S18-2 and RB in the pluripotency of cells, the four cell lines were 
subjected to directed differentiation using cocktails of chemicals. 
Dexamethasone, ascorbic acid 2-phosphate and glycerol 2-phosphate were used to induce 
osteogenesis. It has been reported that dexamethasone induced Runx2 expression through 
FHL2/β-catenin-mediated transcriptional activation. Moreover; dexamethasone increased 
Runx2 activity by upregulation of tafazzin and MAP kinase phosphatase 1. Ascorbic acid 
increases the secretion of collagen type I (Col1), which in turn leads to increased Col1/α2β1 
integrin-mediated intracellular signaling. The glycerol 2 phosphate provides a source of 
phosphate in hydroxylapatite and in addition influences intracellular signaling molecules 
[226]. The robust effect of this cocktail of chemicals leads to differentiation of pluripotent 
SCs to bone forming progenitor cell, the osteoblasts. To stain osteoblast in cell cultures 
Alizarin red S solution was used. The Runx2 is the main transcription factor regulating the 
osteogenic differentiation that was upregulated in RH18RB cells after differentiation 
induction. Furthermore, Osp was also highly expressed in RH18RB cells that is one of the 
Runx2 responsive genes and is also believed as marker of osteogenesis. The Osp helps in 
bone remodeling via integrin mediated pathway in osteoblasts and osteoclasts by directly 
binding to integrin αVβ3 [227]. 
After treatment for the induction of chondrogenic differentiation, cells were treated with 
acidic solution of Alcian blue that stained the proteoglycans of chondrocytes. Sox9 is the 
transcription factor that regulates the chondrogenic differentiation. Sox9 controls the 
expression of aggrecan that is a critical component for cartilage structure and carries the 
binding domain for hyaluronic acid (HA). Aggrecan plays an important role in mediating 
chondrocyte-matrix and chondrocyte-chondrocyte interactions through its ability to bind HA 
and linker proteins. We showed that in the presence of RB and S18-2 overexpression 
(RH18RB cells) Sox9 expression was elevated both at mRNA and protein level. 
Previously it has been reported that RB promotes the differentiation of multiple lineages by 
monitoring the activity of master transcription factors such as MyoD in muscles [207], Runx2 
in bones [228], and PGC-1 in adipocytes [229]. However, RB individually as well as highly 
expressed S18-2 alone was not sufficient to drive the differentiation of SCs. But the presence 
of RB simultaneously with highly expressed S18-2 could drive the differentiation of SCs to 
different cell lineage. 
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3.5.3 Tumorigencity of cells 
The RH and RHRB cells failed to grow even after 20 weeks of injection. Both RH18 and 
RH18RB cells produced tumors in mice, RH18RB cells were highly tumorigenic as tumor 
appeared with in three weeks in RH18RB injected mice. The tumor initiated very quickly and 
they were also larger in size (14 mm
3
) compared to RH18 tumors. 
A portion of RH18 tumors appeared like epithelial cells and few necrotic cells were also 
observed in those tumors. RH18RB tumors were more aggressive and without necrotic cells 
in tumors. The RH18RB tumor cells expressed Pan-keratin and very few cells showed strong 
expression of cytokeratin 18. They lost the expression of vimentin. 
3.5.4 S18-2 and RB maintain cell stemness and differentiation by enhancing 
the RNF2 activity 
Using the GST pulldown assay it was demonstrated that S18-2 can bind to Rnf2. The effect 
of this association was analyzed with high expression and endogenous expression of S18-2 
both in the presence and absence of RB. The Rnf2 was expressed at the same level in all four 
cell types. The activity of Rnf2 was assessed by analyzing the levels of Ub-K119 H2A. The 
highest activity of Rnf2 was detected in RH18RB cells, moderate levels in RHRB cells but 
relatively lower in RH18 cells while Rnf2 was inactive in RH cells. It indicates that Rnf2 
needed RB for its function but the highest activity was observed with the overexpression of 
S18-2 and RB together. 
Polycomb group proteins (PcG) are well known for their control of gene expression via 
chromatin modification during development [230]. The PcG is an assembly of several 
proteins, in the form of two complexes: polycomb repressor complex (PRC) I and II. The 
PcG proteins regulate gene expression with a repressive function that is stable over many cell 
generations. The Ring1B or Rnf2 is one of the members of PRC-I, it has been shown to 
interact with and silence the activity of CP2 (TFCP2/CP2) transcription factors [231]. The 
role of Rnf2 has been studied in different cellular processes like embryogenesis, 
development, self-renewal, differentiation and cancer. Rnf2 is an ubiquitin E3 ligase enzyme; 
it suppresses the expression of target genes through mono-ubiquitination of lysine 119 of 
histone H2A (Ub-K119-H2A). RING1, another protein of PRC1 act as modulator of RNF2 
and it is required for RNF2 activity.  
 It has been shown that Rnf2 contributes to stable maintenance of mouse ESCs. 
Rnf2/Oct4/Nanog could bind to 212 common genes, with the deficiency of RinG1B the 
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expression of 25 genes was found altered [116, 232, 233]. Out of the 25 genes 18 were de-
repressed following the knockout of Rnf2 in mouse ESCs. This suggests that Rnf2 is required 
for the maintenance of undifferentiated and pluripotent SCs by repression of specific subsets 
of Oct4 and Nanog associated genes. Some of the Nanog and Oct4 co-occupied 18 genes 
were Gadd45g, Fgf15, Bmp7, Col4a2, Podxl, Gata3, Bmi1, Msx2, Gja1 and Eif4g3 [233]. 
The Rnf2 was found completely inert in the absence of RB with endogenous expression of 
S18-2 (RH cells). Lower activity of Rnf2 was associated with the expression of RB at 
physiological level of S18-2. Even some activity of Rnf2 was observed with S18-2 
overexpression alone in the absence of RB, but Rnf2 was highly active with the 
overexpression of S18-2 and RB (RH18RB cells), together. 
These data suggest that RB binds to RING1 and S18-2 interact with Rnf2, but RB and S18-2 
also interact with each other which might bring RING1 and Rnf2 in close proximity. Such 
interactions result in highly ubiquitination of H2A which is important for stem cell identity as 
shown in Figure 8. The deficiency of Rnf2 resulted in the embryonic lethality and caused the 
gastrulation arrest as well as cell cycle inhibition [234]. Furthermore, Rnf2 is required for 
chondrocyte and osteocyte differentiation in zebrafish by stabilizing the expression of 
transcription factors RUNX2 and SOX9 that are needed for the differentiation of these 
lineages [235]. It has been found that Rnf2 raised the expression of Sox9 by inhibiting the 
expression of its repressor, the Msx2 [233, 236]. We also reported in the current study that 
overexpression of S18-2 and RB; increased the Rnf2 activity, induced the differentiation and 
the expression of both SOX9 and RUNX2. And knockdown of S18-2 in zebrafish embryos 
induces embryonic lethality. 
3.5.5 Role of S18-2 in development of zebrafish embryos 
The S18-2 expression in zebrafish embryos reached a maximum level in the period of 4–6 
hpf. Knockdown of the S18-2 protein in zebrafish embryos induced embryonic lethality. 
Moreover, the embryos exhibited a severely abnormal phenotype: they were significantly 
smaller in size, their endoderm was underdeveloped, and segmentation did not occur. In 
zebrafish embryos, the S18-2 gene was disrupted via transposon mutagenesis that resulted in 
truncation of first 75 residues of corresponding protein. The fish died at post-fertilization day 
10 because of impaired cardiac contractility [237]. The function of S18-2 in embryogenesis 
should be further elucidated. 
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3.6 PAPER VI 
The S18-2 immortalized REFs (18IM) which are described above were used in this study. 
18IM cells showed all the characteristics of SCs but unlike SCs they failed to give rise to 
tumor in experimental animals. To study such asymmetrical behavior of these cells they were 
challenged to NK cell mediated cytotoxicity and directed differentiation in vitro.  
It has been shown that NK cells target the embryonic SCs or cancer initiating cells compared 
to differentiated cells. One of the reason is their reduced expression of MHC I proteins. It is 
reported that ESCs and cancer initiating cells expressed MHC I at very low levels [238]. 
18IM cells also showed very low expression of MHC I molecule compared to control REF. 
In vitro, 18IM cells were presented to IL-2 activated rat splenocytes of same species from 
which the parental REFs were previously isolated to generate the 18IM cells. They were 
better recognized and killed compared to control REF as measured by chromium release 
assay. When the NK activating receptor of these splenocytes was blocked by antibody, 18IM 
killing was reduced. The similar behavior was observed when NK cells were used from SCID 
mice in which 18IM cells failed to produce tumors. The chemokine, cytokine and their 
receptor was measured most of those molecules that raised the cytotoxic activity of NK cells 
were upregulated at mRNA level in 18IM cells compared to REFs. Finally, the NK cells were 
shown by to be recruited in vivo to the site of 18IM injection.  
Another possibility of asymmetric behavior might be the trans-differentiation of SCs like 
18IM cells. In vitro 18IM cells challenged for directed differentiation to different cell 
lineages like osteogenesis, chondrogenesis. Probably the cells acquired all the factors 
required for differentiation and trans-differentiated instead of proliferation.  
Concluding, the overexpression of S18-2 enhance the tumorigenesis and evoke NK cell 
cytotoxicity due to decreased MHC I expression. S18-2 might be selected for targeted therapy 
against cancer. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
In the light of results described in the current doctoral thesis, we characterized the role of 
MRPS18-2, a RB interacting protein, in the control of several cellular processes, including 
proliferation, stemness and differentiation. 
The S18-2 protein belongs to the S18 family, which includes a group of proteins, conserved 
through evolution. We described the “rise” of S18 proteins from bacteria to metazoans, 
identifying conserved residues in all the three S18 proteins. These finding might be helpful to 
find the normal physiological functions of S18 proteins which are still unknown. 
Phylogenetic analysis of S18 proteins revealed specific gene duplication events that resulted 
in three S18 homologs in metazoan. 
We found that overexpressed S18-2 can immortalize the terminally differentiated primary 
rodent cells. These cells show chromosomal instability, enhanced telomerase activity and 
tumorigenecity in SCID mice. The rodent cells immortalized by overexpression of S18-2 
were targeted by NK cell mediated cytotoxicity. The NK cell immunogenicity make S18-2 a 
putative target for future therapies against cancer. 
The differential expression of S18-2 in endometrial cancer, prostate cancer and a consensus 
Gly132 polymorphism of S18-2 in colon cancer enlighten the role of S18-2 in tumorigenesis. 
We demonstrated that S18-2 can induce EMT in EC and PCa. Moreover, overexpressed S18-
2 induced the CXCR4 mediated migration of PCa cells in vitro and in a zebrafish model. Our 
findings describe the new mechanism of cell migration induced by S18-2 overexpression as a 
putative molecular mechanism underlying metastasis.  
We revealed the new functional consequences of RB-S18-2 interaction in the control of cell 
stemness and differentiation. A cytoplasmic protein complex between S18-2, RB, and the 
RNF2 was detected. Such interactions enhanced the E3 ligase activity of RNF2, thus, 
maintaining cell stemness. This finding may open a new insight in the regulation of 
differentiation which is a major challenge in the application of stem cell biology.  
The data described in this doctoral thesis strongly suggest that S18-2 plays an important role 
in the development of cancer as a potent oncoprotein. Important questions for the future 
include: 1) Elucidation of the physiological function of S18-2; 2) Understanding the role its 
CXXC zinc finger DNA binding motif; 3) Analyzing the status of S18-2 in other human 
tumors, particularly in tumors where RB is deleted or mutated; 4) The binding between S18-2 
and RB at different stages of cell cycle should be analyzed as it may reveal a novel 
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mechanism of cell cycle regulation; 5) The role of S18-2 in embryogenesis must be further 
studied.  
The justification of these studies from a cancer therapy perspective is that S18-2 could be an 
attractive target for development of future cancer therapies.  
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